Home » Stocks » NEOS

Neos Therapeutics, Inc. (NEOS)

Stock Price: $0.573 USD -0.001 (-0.23%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $0.570 -0.003 (-0.52%) Nov 27, 4:34 PM

Stock Price Chart

Key Info

Market Cap 28.51M
Revenue (ttm) 56.99M
Net Income (ttm) -21.86M
Shares Out 49.76M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $0.573
Previous Close $0.574
Change ($) -0.001
Change (%) -0.23%
Day's Open 0.560
Day's Range 0.560 - 0.606
Day's Volume 522,823
52-Week Range 0.450 - 1.980

More Stats

Market Cap 28.51M
Enterprise Value 59.71M
Earnings Date (est) Mar 18, 2021
Ex-Dividend Date n/a
Shares Outstanding 49.76M
Float 48.43M
EPS (basic) -0.44
EPS (diluted) -0.44
FCF / Share -0.14
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.13M
Short Ratio 1.30
Short % of Float 4.40%
Beta 1.73
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 0.50
PB Ratio n/a
Revenue 56.99M
Operating Income -13.39M
Net Income -21.86M
Free Cash Flow -6.99M
Net Cash -31.20M
Net Cash / Share -0.63
Gross Margin 69.35%
Operating Margin -23.50%
Profit Margin -38.40%
FCF Margin -12.26%
ROA -10.71%
ROE n/a
ROIC -45.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 3
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(859.86% upside)
Current: $0.573
Target: 5.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth29.33%84.24%170.43%164.58%400.26%-27.39%-
Gross Profit39.5323.0613.10-1.70-2.14-2.63-1.49
Operating Income-10.42-43.50-56.54-75.82-26.58-18.47-17.09
Net Income-16.90-51.68-65.77-82.75-30.78-20.85-15.63
Shares Outstanding49.7232.2924.7516.057.580.880.79
Earnings Per Share-0.34-1.60-2.66-5.16-4.38-27.56-28.45
Operating Cash Flow-10.78-41.44-53.26-70.65-25.87-17.39-14.96
Capital Expenditures-1.09-1.36-2.50-3.55-1.02-0.34-2.02
Free Cash Flow-11.87-42.80-55.76-74.20-26.89-17.73-16.97
Cash & Equivalents24.8946.4850.4239.7890.7616.34-
Total Debt48.8751.7759.8363.5234.2424.77-
Net Cash / Debt-23.98-5.30-9.42-23.7456.52-8.43-
Book Value-6.137.858.95-1.5578.37-78.78-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Neos Therapeutics, Inc.
Country United States
Employees 213
CEO Gerald W. McLaughlin

Stock Information

Ticker Symbol NEOS
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: NEOS
IPO Date July 23, 2015


Neos Therapeutics, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.